AbbVie Completes Acquisition of Landos Biopharma

AbbVie completed its acquisition of clinical-stage biopharmaceutical company Landos Biopharma for $20.42 per share in cash, plus a contingent value right (CVR) tied to a clinical milestone. The deal adds Landos’ first-in-class investigational asset NX-13 to AbbVie’s immunology pipeline for potential treatment of ulcerative colitis and Crohn’s disease.